<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051232</url>
  </required_header>
  <id_info>
    <org_study_id>A8121035</org_study_id>
    <nct_id>NCT01051232</nct_id>
  </id_info>
  <brief_title>A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers</brief_title>
  <official_title>A Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 (Filibuvir) Following Single Oral Administrations Of PF-00868554 (Filibuvir) Under Fasting Conditions In Japanese Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose of PF-00868554 (filibuvir) will be safety and tolerable in Japanese healthy
      volunteers. The pharmacokinetics in Japanese will be consistent to that available in Western
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigation of safety, tolerability and pharmacokinetics of single oral administration of
      PF-00868554 (filibuvir) in healthy adult Japanese volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety; ECGs/vital signs</measure>
    <time_frame>Screening to Follow-up (Day 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety; laboratory tests</measure>
    <time_frame>Screening to Follow-up (Day 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety; physical examination/adverse event monitoring</measure>
    <time_frame>Screening to Follow-up (Day 5)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics; Plasma PF-00868554 (filibuvir) concentrations</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics; Urine PF-00868554 (filibuvir) concentrations</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PF-00868554 (filibuvir) 100 mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PF-00868554 (filibuvir) 300 mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PF-00868554 (filibuvir) 500 mg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two subjects will receive the placebo under fasting condition.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two subjects will receive the placebo under fasting condition.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two subjects will receive the placebo under fasting condition.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects between the ages of 20 and 55 years.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg.

        Exclusion Criteria:

          -  A positive result for Hepatitis B surface antigen (HbsAg) or anti-hepatitis C virus
             serology, and HIV antigen/antibody.

          -  Male subjects with a history of subfertility/infertility and other conditions that in
             the opinion of the investigator may affect fertility.

          -  Pregnant or nursing females; females of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8121035&amp;StudyName=A%20Study%20To%20Investigate%20Safety%20And%20Pharmacokinetics%20Of%20A%20Single%20Dose%20Of%20PF-00868554%20%28Filibuvir%29%20In%20Japanese%20Healthy%20Adult%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>April 22, 2010</last_update_submitted>
  <last_update_submitted_qc>April 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>filibuvir</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Japanese</keyword>
  <keyword>Asian</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

